Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Koehler K, Liebner D, Chen JL. Koehler K, et al. Among authors: chen jl. Ann Oncol. 2016 Mar;27(3):539-43. doi: 10.1093/annonc/mdv598. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646755 Free PMC article.
RESULTS: Mutations that were observed in at least 20% of patients included TP53 and Rb1. Only TP53 was predictive of PFS in the context of VEGFR inhibition. The PFS of patients with TP53 mutations was significantly greater than TP53 wild-type tumors wi …
RESULTS: Mutations that were observed in at least 20% of patients included TP53 and Rb1. Only TP53 was predictive of PFS in th …
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Seligson ND, Stets CW, Demoret BW, Awasthi A, Grosenbacher N, Shakya R, Hays JL, Chen JL. Seligson ND, et al. Among authors: chen jl. Oncotarget. 2019 Oct 1;10(55):5671-5679. doi: 10.18632/oncotarget.27144. eCollection 2019 Oct 1. Oncotarget. 2019. PMID: 31620242 Free PMC article.
RNA-sequencing of romidepsin treated mouse tumors demonstrated markers of TP53 reactivation. Taken together, our data supports the hypothesis that targeting HDAC2 may represent a potential strategy to modulate MDM2 expression in DDLPS....
RNA-sequencing of romidepsin treated mouse tumors demonstrated markers of TP53 reactivation. Taken together, our data supports the hy …
Feedback